Novel medicines focused on the BIG Axis

We are advancing a rich pipeline of innovative therapies across two divisions.

 

Our Internal pipeline

Our Internal pipeline leverages new insights into lymphatic biology and immune cell trafficking to develop novel therapeutics.

Immunology with a focus on lymphatics and immune cell trafficking

Utilizing the recently described brain lymphatic network to target neurodegenerative and CNS autoimmune diseases  
Modulation of lymphocyte function and drug transport with lipid prodrugs  
Oral administration of therapeutics, including biologics, into the lymphatic system  
Modulation of lymphocyte trafficking and function by targeting immunosuppressive gamma delta T-cells  

CNS Lymphatics Technology

Emerging evidence suggests that the lymphatic system may play a critical role in the health of the central nervous system (CNS). The recently discovered association between the meningeal lymphatic system and the CNS shed new light on the previously accepted rules of human biology, such as CNS immune privilege. These insights around the CNS-immune interface underlie our approach to designing novel categories of therapeutics to address debilitating and devastating CNS disorders.

MORE

Lymphatic Targeting Technology

Our lipid prodrug approach harnesses the body’s natural lipid transport mechanisms to substantially enhance the transport of oral small molecules directly into the lymphatic system. This pathway facilitates entry into the mesenteric lymph nodes, the critical site for immune cell priming and proliferation in the GI tract. As about 80 percent of immune cells reside in the GI tract-associated lymphatic tissues, targeting of immunomodulatory agents with this approach can tune both systemic and local immune status. In pursuit of this objective, we have successfully extended the platform to new drugs and linker chemistries, which continue to demonstrate promising lymphatic targeting in preclinical studies.

MORE

Milk Exosomes Technology

Our milk exosome-based technology is uniquely designed to facilitate the oral administration of complex payloads such as nucleic acids, peptides, and small molecules. These exosomes are believed to traffic via lymphatic circulation and could potentially enable the targeting of immune cells in ways not technically feasible before. There is a significant body of published data underscoring the potential application of exosomes from a therapeutic delivery and physiological modulation perspective. Our internal work builds on these published findings and has generated a significant amount of unpublished data that will be shared in the appropriate scientific forum.

MORE

Immunosuppressive Gamma Delta T-Cells

We are developing first-in-class monoclonal antibodies targeting immunosuppressive gamma delta T-cells, galectin-9 and related novel mechanisms in pancreatic cancer, colorectal cancer and other solid tumors. Our therapeutics are aimed at oncology indications that have dismal prognosis and are currently suboptimally treated with available standard of care agents and immunotherapies. We are conducting safety and efficacy validation of our lead therapeutic candidates, in preparation for the first clinical trial.  

MORE
Utilizing the recently described brain lymphatic network to target neurodegenerative and CNS autoimmune diseases

CNS Lymphatics Technology

Emerging evidence suggests that the lymphatic system may play a critical role in the health of the central nervous system (CNS). The recently discovered association between the meningeal lymphatic system and the CNS shed new light on the previously accepted rules of human biology, such as CNS immune privilege. These insights around the CNS-immune interface underlie our approach to designing novel categories of therapeutics to address debilitating and devastating CNS disorders.

MORE

Modulation of lymphocyte function and drug transport with lipid prodrugs

Lymphatic Targeting Technology

Our lipid prodrug approach harnesses the body’s natural lipid transport mechanisms to substantially enhance the transport of oral small molecules directly into the lymphatic system. This pathway facilitates entry into the mesenteric lymph nodes, the critical site for immune cell priming and proliferation in the GI tract. As about 80 percent of immune cells reside in the GI tract-associated lymphatic tissues, targeting of immunomodulatory agents with this approach can tune both systemic and local immune status. In pursuit of this objective, we have successfully extended the platform to new drugs and linker chemistries, which continue to demonstrate promising lymphatic targeting in preclinical studies.

MORE
Oral administration of therapeutics, including biologics, into the lymphatic system

Milk Exosomes Technology

Our milk exosome-based technology is uniquely designed to facilitate the oral administration of complex payloads such as nucleic acids, peptides, and small molecules. These exosomes are believed to traffic via lymphatic circulation and could potentially enable the targeting of immune cells in ways not technically feasible before. There is a significant body of published data underscoring the potential application of exosomes from a therapeutic delivery and physiological modulation perspective. Our internal work builds on these published findings and has generated a significant amount of unpublished data that will be shared in the appropriate scientific forum.

MORE
Modulation of lymphocyte trafficking and function by targeting immunosuppressive gamma delta T-cells

Immunosuppressive Gamma Delta T-Cells

We are developing first-in-class monoclonal antibodies targeting immunosuppressive gamma delta T-cells, galectin-9 and related novel mechanisms in pancreatic cancer, colorectal cancer and other solid tumors. Our therapeutics are aimed at oncology indications that have dismal prognosis and are currently suboptimally treated with available standard of care agents and immunotherapies. We are conducting safety and efficacy validation of our lead therapeutic candidates, in preparation for the first clinical trial.  

MORE

Collaborating with Industry Leaders Across Our Affiliate and Internal Pipelines

Amgen Novartis Shire Pfizer Lilly Merck Johnson & Johson Roche

CASE STUDIES

DISCOVERY REINVENTED

  • Aging related immune disorders
  • Gut/Immune Ecosystem
  • Severe and Chronic Mental Health